Form 8-K · Current Report · Filed 2026-08-04
Revvity Announces Q2 2026 Financial Results and China IDX Divestiture
Revvity, Inc. reported its financial results for the second quarter of 2026, showing revenue of $730 million and adjusted earnings per share (EPS) of $1.41. The company also announced the entry into a definitive agreement to divest its Immunodiagnostics business in China for up to $200 million. Pro forma financial results, excluding China IDX, showed revenue of $711 million and adjusted EPS of $1.41. Revvity raised its full-year 2026 guidance for pro forma organic revenue growth and pro forma adjusted EPS.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-26-000022
- CIK
- 0000031791
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$115.22
Next session
-0.2%
Since filing
+27.3%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, RVTY insiders reported 8 Form 4 transactions — net selling of $9K.
About Revvity Inc.
Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.